Effect of Acute Administration of L-Dopa on Serum Concentrations of Follicle-Stimulating Hormone (FSH) and Luteinizing Hormone (LH) in Patients with the Amenorrhea-Galactorrhea Syndrome

Zárate, Arturo; Canales, Elías S.; Soria, J; Maneiro, Pedro J.; MacGregor, Carlos

doi:10.1159/000122185

Cited by 14 publications

(3 citation statements)

References 3 publications

(3 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Nonetheless, our findings lend further support to the idea that dopaminergic neuronal activity may play an important role in the regulation of LH secretion in humans (19). The effect of L-dopa on gonadotropin release has been examined by several investigators in the past (9)(10)(11)(12)(13). The failure to disclose a clear effect is due to the fact that most of these earlier investigators were looking for a rise rather than for a fall in LH levels (9)(10)(11).…”

Section: Discussionsupporting

confidence: 82%

“…The effect of L-dopa on gonadotropin release has been examined by several investigators in the past (9)(10)(11)(12)(13). The failure to disclose a clear effect is due to the fact that most of these earlier investigators were looking for a rise rather than for a fall in LH levels (9)(10)(11). Their reasoning stemmed from the experimental data in rats which indicated that dopamine enhances the release of hypothalamic LRF (20,21).…”

Section: Discussionmentioning

confidence: 99%

“…The demonstration of an inhibitory effect of L-dopa and CB-154 on LH release adds further support to the role of dopaminergic control of pituitary LH secretion. (/ Clin Endocrinol Metub 44: 728, 1977) W HILE the acute inhibitory effects of orally administered dopamine agonists, L-dopa and 2-bromo-«-ergocryptine (CB-154), on prolactin (PRL) release are well established (1)(2)(3)(4)(5)(6)(7)(8), several investigators have failed to demonstrate any specific acute effect of L-dopa or CB-154 on gonadotropin secretion (8)(9)(10)(11)(12). Boden et al (13), however, did detect a significant decrease in LH levels during a 3 h experiment following the ingestion of 0.5 g L-dopa in human subjects.…”

mentioning

confidence: 99%

See 2 more Smart Citations

The Inhibitory Effect of Dopamine Agonists on LH Release in Women¹

Lachelin

Leblanc

Yen

1977

The Journal of Clinical Endocrinology & Metabolism

152

View full text Add to dashboard Cite

Our demonstration of an inhibitory effect of dopamine on LH release prompted us to examine whether a similar action exists for dopamine agonists, such as L-dopa and 2-bromo-alpha-ergocryptine (CB-154). Following the administration of L-dopa (0.5 g, orally) to 6 normal women in the early follicular phase, a significant fall in mean LH levels after 1 h which lasted for 5 h was observed (P less than 0.00005). This was followed by a significant rebound above basal levels between the 7th and 10th h (P less than 0.00005). The expected fall in mean PRL levels which lasted for 4 h (P less than 0.00001) was followed by a significant rebound above basal levels after the 6th h (P less than 0.00001)). There was no significant change in mean FSH levels. Following the administration of CB-154 (2.5 mg. orally) to 6 women with hyperprolactinemic amenorrhea, there was also a significant fall in LH levels (P less than 0.00001) and in FSH levels (P less than 0.00001) from 5 h until the study ended at 10 h. The anticipated PRL suppression was also observed and persisted for the duration of the 10 h study. The demonstration of an inhibitory effect of L-dopa and CB-154 on LH release adds further support to the role of dopaminergic control of pituitary LH secretion.

show abstract

Section: Discussionsupporting

confidence: 82%

Section: Discussionmentioning

confidence: 99%

mentioning

confidence: 99%

See 1 more Smart Citation

The Inhibitory Effect of Dopamine Agonists on LH Release in Women¹

Lachelin

Leblanc

Yen

1977

The Journal of Clinical Endocrinology & Metabolism

152

View full text Add to dashboard Cite

show abstract

Studies of the Role of Dopamine in the Control of Prolactin and Gonadotropin Secretion in Humans

Yen

1979

Central Regulation of the Endocrine System

View full text Add to dashboard Cite

Acute effects of L-dopa and bromocriptine on serum PRL, LH and FSH levels in patients with hyperprolactinemic and normoprolactinemic polycystic ovary syndrome

Prelević

Würzburger²,

Perić³

1987

J Endocrinol Invest

View full text Add to dashboard Cite

We have investigated the importance of the dopaminergic control of gonadotropin secretion by studying LH, FSH and PRL responses to L-dopa and bromocriptine in patients with polycystic ovary syndrome (PCOS). Both L-dopa and bromocriptine administration were followed by a statistically significant decrease in LH in the hyperprolactinemic PCO patients (compared to the normoprolactinemic subgroup - p less than 0.01 and control group - p less than 0.05); the decline was proportional to the basal level of LH. A significant positive correlation between basal LH levels and maximum net decrease of LH was observed after administration of both agents (p less than 0.01). Although both subgroups of PCO patients showed a similar decrease in PRL levels it was statistically significant only in the normoprolactinemic patients (p less than 0.01). Prolactin sensitivity to the inhibitory effect of bromocriptine and L-dopa showed a significant correlation with the basal PRL level (p less than 0.01). The response of serum FSH was variable and not significant. These results suggest that a reduction of an inhibitory influence of hypothalamic dopamine might be a cause of inappropriately elevated LH and PRL levels found in patients with polycystic ovary syndrome and hyperprolactinemia.

show abstract

Effect of Acute Administration of L-Dopa on Serum Concentrations of Follicle-Stimulating Hormone (FSH) and Luteinizing Hormone (LH) in Patients with the Amenorrhea-Galactorrhea Syndrome

Cited by 14 publications

References 3 publications

The Inhibitory Effect of Dopamine Agonists on LH Release in Women¹

The Inhibitory Effect of Dopamine Agonists on LH Release in Women¹

Studies of the Role of Dopamine in the Control of Prolactin and Gonadotropin Secretion in Humans

Acute effects of L-dopa and bromocriptine on serum PRL, LH and FSH levels in patients with hyperprolactinemic and normoprolactinemic polycystic ovary syndrome

Contact Info

Product

Resources

About

Effect of Acute Administration of L-Dopa on Serum Concentrations of Follicle-Stimulating Hormone (FSH) and Luteinizing Hormone (LH) in Patients with the Amenorrhea-Galactorrhea Syndrome

Cited by 14 publications

References 3 publications

The Inhibitory Effect of Dopamine Agonists on LH Release in Women1

The Inhibitory Effect of Dopamine Agonists on LH Release in Women1

Studies of the Role of Dopamine in the Control of Prolactin and Gonadotropin Secretion in Humans

Acute effects of L-dopa and bromocriptine on serum PRL, LH and FSH levels in patients with hyperprolactinemic and normoprolactinemic polycystic ovary syndrome

Contact Info

Product

Resources

About

The Inhibitory Effect of Dopamine Agonists on LH Release in Women¹

The Inhibitory Effect of Dopamine Agonists on LH Release in Women¹